Cerus (NASDAQ:CERS) Insider Sells $48,712.35 in Stock

March 10, 2026 by InsiderTrades.com

Key Points

Insider sale: Richard Benjamin sold 61,233 shares on March 5 at an average of $2.06 for about $126,140, cutting his stake ~6.09% to 943,762 shares, and this trade is part of a broader cluster of insider sales (CEO, COO, CFO) during Mar 5–9 that could weigh on sentiment.
Mixed financials: Cerus beat revenue expectations with $64.58M for the quarter but reported a negative EPS of ($0.01) and continues to show a negative net margin and return on equity, leaving the company unprofitable.
Institutional positioning: Several institutions (notably AQR, Cubist, and Millennium) substantially increased holdings and institutional investors now own about 78.37% of the stock, while analyst ratings remain mixed with an average "Hold."

Cerus Corporation (NASDAQ:CERS - Get Free Report) insider Richard Benjamin sold 24,235 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $2.01, for a total transaction of $48,712.35. Following the transaction, the insider owned 919,527 shares in the company, valued at $1,848,249.27. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Cerus Stock Performance

Shares of CERS opened at $1.93 on Tuesday. The firm has a market cap of $370.89 million, a price-to-earnings ratio of -24.13 and a beta of 1.51. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73. Cerus Corporation has a fifty-two week low of $1.12 and a fifty-two week high of $2.96. The firm has a 50 day moving average price of $2.31 and a 200-day moving average price of $1.86.

Cerus (NASDAQ:CERS - Get Free Report) last released its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The company had revenue of $64.58 million for the quarter, compared to analyst estimates of $59.31 million. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. As a group, equities research analysts forecast that Cerus Corporation will post -0.08 earnings per share for the current year.

Trending Headlines about Cerus

Here are the key news stories impacting Cerus this week:

Neutral Sentiment: Short-interest data flagged an apparent increase for the March 9 reporting period but shows 0 shares and reports a days-to-cover of 0.0 — the print looks incorrect or incomplete and should be treated as unreliable until exchanges update filings.
Neutral Sentiment: Analysts overview: The Globe and Mail ran a piece discussing analysts' views on Cerus alongside peers (Fennec). That coverage provides context but does not appear to contain new company-specific catalysts. Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Fennec Pharmaceuticals (FENC)
Negative Sentiment: Insider selling: several insiders disclosed sales between Mar. 5–9 that reduce insider ownership by low-single-digit to mid-single-digit percentages. Notable filings: CEO William Mariner Greenman sold 78,187 shares (~$157k). COO Vivek Jayaraman sold 34,094 shares (~$68.5k). CFO Kevin D. Green sold 27,796 shares (~$55.9k). Director Richard J. Benjamin reported multiple sales (61,233; 40,426; 24,235 shares) at ~$2.06–$1.88 across Mar. 5–9. Insider Chrystal Jensen sold 30,845 shares (~$62k). Collectively, these are meaningful in signaling added supply and may weigh on sentiment even if sales were for personal/liquidity reasons. CEO filing: http://www.sec.gov/Archives/edgar/data/1020214/000137725826000004/xslF345X05/ownership.xml COO filing: http://www.sec.gov/Archives/edgar/data/1020214/000160545626000004/xslF345X05/ownership.xml Chrystal Jensen filing: http://www.sec.gov/Archives/edgar/data/1020214/000156425226000004/xslF345X05/ownership.xml Richard Benjamin filings: http://www.sec.gov/Archives/edgar/data/1020214/000129632226000004/xslF345X05/ownership.xml CFO filing: http://www.sec.gov/Archives/edgar/data/1020214/000145935126000005/xslF345X05/ownership.xml

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wall Street Zen downgraded Cerus from a "buy" rating to a "hold" rating in a report on Saturday. TD Cowen restated a "buy" rating on shares of Cerus in a report on Monday, January 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold".

Get Our Latest Stock Analysis on CERS

Institutional Investors Weigh In On Cerus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC boosted its position in Cerus by 152.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company's stock valued at $145,000 after buying an additional 62,854 shares during the period. AQR Capital Management LLC increased its position in shares of Cerus by 291.6% in the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company's stock valued at $1,986,000 after acquiring an additional 1,064,133 shares during the period. Millennium Management LLC increased its position in shares of Cerus by 12.0% in the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock valued at $4,479,000 after acquiring an additional 344,395 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Cerus during the first quarter valued at about $32,000. Finally, Savant Capital LLC raised its stake in shares of Cerus by 339.6% during the second quarter. Savant Capital LLC now owns 94,812 shares of the biotechnology company's stock valued at $134,000 after acquiring an additional 73,244 shares during the last quarter. 78.37% of the stock is currently owned by institutional investors.

Cerus Company Profile

(Get Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.